文献速递甲状腺核医学肿瘤 PET/CT

颈部超声、99mTc-甲氧基异丁基异腈闪烁显像与增强18F-氟胆碱PET/CT在原发性甲状旁腺功能亢进症中的诊断效能比较

Diagnostic Performance of Cervical Ultrasound, 99mTc-Sestamibi Scintigraphy, and Contrast-Enhanced 18F-Fluorocholine PET in Primary Hyperparathyroidism.
PubMed 文献 · J Nucl Med · 2021-12-02

该回顾性研究纳入144例临床疑似原发性甲状旁腺功能亢进症患者,比较增强18F-氟胆碱PET/CT、颈部超声与常规MIBI闪烁显像单独及联合术前定位功能亢进甲状旁腺的效能,以组织学为金标准。18F-氟胆碱PET/CT敏感度99.3%、准确率98%,均优于颈部超声、MIBI闪烁显像及两者联合。

要点

  • 18F-氟胆碱PET/CT敏感度99.3%,高于颈部超声75.2%、MIBI闪烁显像65.1%及两者联合89.9%。
  • 18F-氟胆碱PET/CT准确率98%,高于颈部超声84%、MIBI闪烁显像81%及两者联合91%。
  • 在颈部超声联合MIBI闪烁显像阴性的72例(50%)患者中,18F-氟胆碱PET/CT正确识别70例(97.2%)。

核心结论

  • 18F-氟胆碱PET/CT定位功能亢进甲状旁腺的准确率高于颈部超声和MIBI闪烁显像。
  • 作者认为该结果支持将18F-氟胆碱PET/CT作为原发性甲状旁腺功能亢进症诊断的一线方法系统使用。

研究设计与样本

  • 回顾性连续收集临床疑似原发性甲状旁腺功能亢进症患者的数据。
  • 所有患者均系统接受增强18F-氟胆碱PET/CT、颈部超声和MIBI闪烁显像三种检查。
  • MIBI闪烁显像包括99mTc-甲氧基异丁基异腈/123I-碘化钠SPECT/CT、平面减影显像和平面双相显像。
  • 以组织学检查为金标准,病理甲状旁腺的复合判断标准为组织学分析联合甲状旁腺激素和钙水平正常化。
  • 纳入144例患者,其中143例共发现149个病理甲状旁腺。

主要发现

  • 18F-氟胆碱PET/CT诊断149个病理甲状旁腺中的148个,仅4个假阳性和1个假阴性。
  • 18F-氟胆碱PET/CT敏感度99.3%,高于颈部超声75.2%(P < 0.0001)、MIBI闪烁显像65.1%(P < 0.0001)及颈部超声联合MIBI闪烁显像89.9%(P = 0.0009)。
  • 5个异位病灶中,18F-氟胆碱PET/CT诊断5个,MIBI闪烁显像诊断2个,颈部超声诊断0个。
  • 18F-氟胆碱PET/CT准确率98%,高于颈部超声84%(P < 0.0001)、MIBI闪烁显像81%(P < 0.0001)及颈部超声联合MIBI闪烁显像91%(P < 0.0001)。
  • 在颈部超声联合MIBI闪烁显像阴性的72例(50%)患者中,18F-氟胆碱PET/CT正确识别70例(97.2%)功能亢进甲状旁腺。

关键数值与推荐

  • 颈部超声联合MIBI闪烁显像阳性的判定标准为两者分别显示同侧或同一异位位置的功能亢进甲状旁腺,其他结果均判为阴性。
  • 病理甲状旁腺的复合判断标准为组织学分析联合甲状旁腺激素和钙水平正常化。
  • 至少1项检查阳性者接受手术探查。

临床怎么用

  • 作者认为18F-氟胆碱PET/CT可作为原发性甲状旁腺功能亢进症诊断的一线方法系统使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preoperative localization of pathologic parathyroids is crucial for minimally invasive treatment of primary hyperparathyroidism (PHPT). This study compared contrast-enhanced 18F-fluorocholine PET/CT, cervical ultrasonography (CU), and conventional scintigraphic imaging modalities (MIBI scintigraphy, consisting of 99mTc-sestamibi/123I-sodium iodide SPECT/CT, 99mTc-sestamibi/123I-sodium iodide planar subtraction imaging, and 99mTc-sestamibi planar dual-phase imaging), combined and individually, for preoperative localization of hyperfunctional parathyroids in PHPT. The gold standard was histologic examination. Methods: Data from consecutive patients with clinically suspected PHPT were retrospectively collected. All 3 imaging modalities were systematically performed. The ability of 18F-fluorocholine PET/CT, CU, and MIBI scintigraphy to identify a hyperfunctional parathyroid and specify the side or identify an ectopic location was noted. Patients underwent surgical exploration if at least 1 examination was positive. The findings of CU + MIBI scintigraphy combined were considered positive if CU and MIBI scintigraphy separately showed a hyperfunctional parathyroid gland on the same side or in the same ectopic location; any findings other than these were considered negative. The composite judgment criterion for pathologic parathyroid was a combination of histologic analysis and normalization of parathyroid hormone and calcium levels. Results: In total, 149 pathologic parathyroids were found in 143 of the 144 included patients. 18F-fluorocholine PET/CT diagnosed 148 of 149 pathologic parathyroids. Only 4 false-positives and 1 false-negative were found. The 18F-fluorocholine PET/CT sensitivity of 99.3% was superior to that of CU, at 75.2% (P < 0.0001); MIBI scintigraphy, at 65.1% (P < 0.0001); and CU + MIBI scintigraphy, at 89.9%, (P = 0.0009). Five of the 5 ectopic locations were diagnosed by 18F-fluorocholine PET/CT, 2 of the 5 by MIBI scintigraphy, and none by CU. Accuracy was better for 18F-fluorocholine PET/CT, at 98%, than for CU, at 84% (P < 0.0001); MIBI scintigraphy, at 81% (P < 0.0001); or CU + MIBI scintigraphy, at 91% (P < 0.0001). Among the 72 (50%) patients who had a negative CU + MIBI scintigraphy result, 18F-fluorocholine PET/CT correctly identified hyperfunctional thyroids in 70 (97.2%). Average uptake in the 18F-fluorocholine PET/CT hyperfunctional parathyroid was higher than that in the adjacent thyroid (SUVmax adjusted for lean body mass, 6.45 vs. 2.15) (P < 0.0001). Conclusion: The accuracy of 18F-fluorocholine PET/CT is higher than that of CU and MIBI scintigraphy for localization of hyperfunctional parathyroids, justifying the systematic use of 18F-fluorocholine PET/CT as the first-line method for PHPT diagnosis.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Boudousq V, Guignard N, Gilly O, et al. Diagnostic Performance of Cervical Ultrasound, 99mTc-Sestamibi Scintigraphy, and Contrast-Enhanced 18F-Fluorocholine PET in Primary Hyperparathyroidism. J Nucl Med. 2021. PMID: 34857659. doi:10.2967/jnumed.121.261900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。